Older versus newer antidepressants: Substance P or calcium antagonism?

Canadian Journal of Physiology and Pharmacology

Volumn 85, Issue 10, 2007, Pages 1004-1011

  Boselli, C ^a   Barbone, M Santagostino ^a   Lucchelli, A ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Antidepressant; Calcium; Guinea pig ileum; Substance P

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MIANSERIN; MIBEFRADIL; MOCLOBEMIDE; N (ALPHA ETHYLBENZYL) 3 METHYL 2 PHENYL 4 QUINOLINECARBOXAMIDE; NEUROKININ A [4-10][5 TYROSINE 6,8,9 DEXTRO TRYPTOPHAN 10 LYSINE]; NIFEDIPINE; PARGYLINE; PAROXETINE; REBOXETINE; SERTRALINE; SUBSTANCE P; TACHYKININ RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; CALCIUM ANTAGONISM; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEPRESSION; DRUG ACTIVITY; DRUG BINDING; DRUG POTENCY; GUINEA PIG; MALE; NONHUMAN; PKA; PRIORITY JOURNAL; SHIFT TO THE RIGHT;

ANIMALS; ANTIDEPRESSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; CALCIUM CHLORIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ANTAGONISM; GUINEA PIGS; ILEUM; ISOMETRIC CONTRACTION; MALE; RECEPTORS, NEUROKININ-1; SUBSTANCE P;

EID: 38049061501     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/Y07-089     Document Type: Article

References (32)

1. Adell, A. 2004. Antidepressant properties of substance P antagonists: relationship to monoaminergic mechanisms? Curr. Drug Targets CNS Neurol. Disord. 3: 113-121. doi:10.2174/1568007043482516.
2. Arunlakshana, O., and Schild, H.O. 1959. Some quantitative uses of drug antagonists. Br. J. Pharmacol. 14: 48-58.
3. Baby, S., Nguyen, M., Tran, D., and Raffa, R.B. 1999. Substance P antagonists: the next breakthrough in treating depression? J. Clin. Pharm. Ther. 24: 461-469. doi:10.1046/j.1365-2710.1999.00257.x.
4. 2+ exchange-induced 45calcium uptake in synaptosomes from the cortex of the rat brain. Neuropharmacology, 31: 229-234. doi:10.1016/0028-3908(92)90172-L.
5. 45Ca uptake in synaptosomes from rat hippocampus. Psychopharmacology (Berl.), 110: 133-139. doi:10.1007/BF02246962.
6. Carraway, R.E., and Mitra, S.P. 1994. Binding and biologic activity of neurotensin in guinea pig ileum. Peptides, 15: 1451-1459. doi:10.1016/0196-9781(94)90123-6.
7. Chahl, L.A. 2006. Tachykinins and neuropsychiatric disorders. Curr. Drug Targets, 7: 993-1003. doi:10.2174/138945006778019309.
8. Chenu, F., Guiard, B.P., Bourin, M., and Gardier, A.M. 2006. Anti-depressant-like activity of selective serotonin reuptake inhibitors combined with a NK1 receptor antagonist in the mouse forced swimming test. Behav. Brain Res. 172: 256-263. doi:10.1016/j.bbr.2006.05.011.
9. Conley, R.K., Cumberbatch, M.J., Mason, G.S., Williamson, D.J., Harrison, T., Locker, K., et al. 2002. Substance P (neurokinin 1) receptor antagonists enhance dorsal raphe neuronal activity. J. Neurosci. 22: 7730-7736.
10. Froger, N., Gardier, A.M., Moratalla, R., Alberti, I., Lena, I., Boni, C., et al. 2001. 5-hydroxytryptamine (5-HT)1A autoreceptor adaptive changes in substance P (neurokinin 1) receptor knockout mice mimic antidepressant-induced desensitization. J. Neurosci. 21: 8188-8197.
11. Goeringer, K.E., Raymon, L., Christian, G.D., and Logan, B.K. 2000. Postmortem forensic toxicology of selective serotonin re-uptake inhibitors: a review of pharmacology and report of 168 cases. J. Forensic Sci. 45: 633-648.
12. 2+ release from intracellular stores. Neuropharmacology, 49: 265-274. doi:10.1016/j.neuropharm.2005.03.007.
13. Kramer, M.S., Cutler, N., Feighner, J., Shrivastava, R., Carman, J., Sramek, J.J., et al. 1998. Distinct Mechanism for Antidepressant Activity by Blockade of Central Substance P Receptors. Science, 281: 1640-1644. doi:10.1126/science.281.5383.1640.
14. Lacoste, B., Riad, M., and Descarries, L. 2006. Immunocytochemical evidence for the existence of substance P receptor (NK1) in serotonin neurons of rat and mouse dorsal raphe nucleus. Eur. J. Neurosci. 23: 2947-2958. doi:10.1111/j.1460-9568.2006.04833.x.
15. 2+ exchange in rat brain cortex synaptosomes. Can. J. Physiol. Pharmacol. 68: 1414-1418.
16. Lucchelli, A., Santagostino-Barbone, M.G., Dondi, G., and Zonta, F. 1993. Influence of antidepressant drugs on noradrenaline up-3 take and on α1-adrenoceptor activation in the rat vas deferens. Pharmacol. Commun. 4: 29-40.
17. 4 receptors. Br. J. Pharmacol. 114: 1017-1025.
18. Magyar, J., Rusznack, Z., Harasztosi, C., Kortvely, A., Oacher, P., Banyasz Pankucsi, C., et al. 2003. Differential effects of fluoxetine enantiomers in mammalian neural and cardiac tissues. Int. J. Mol. Med. 11: 535-542.
19. McLean, S. 2005. Do substance P and the NK1 receptor have a role in depression and anxiety? Curr. Pharm. Des. 11: 1529-1547. doi:10.2174/1381612053764779.
20. Mousavizadeh, K., Ghafourifar, P., and Sadeghi-Nejad, H. 2002. Calcium channel blocking activity of thioridazine, clomipramine and fluoxetine in isolated rat vas deferens: a relative potency measurement study. J. Urol. 168: 2716-2719. doi:10.1016/S0022-5347(05)64250-4.
21. Pelletier, G., Steinbusch, H.W., and Verhofstad, A.A. 1981. Immunoreactive substance P and serotonin present in the same dense-core vesicles. Nature, 293: 71-72. doi:10.1038/293071a0.
22. Pickel, V.M., Joh, T.H., Reis, D.J., Leeman, S.E., and Miller, R.J. 1979. Electron microscopic localization of substance P and enkephalin in axon terminals related to dendrites of catecholaminergic neurons. Brain Res. 160: 387-400. doi:10.1016/0006-8993(79)91068-0.
23. Rupniak, M.J. 2002. New insights into the antidepressant actions of substance P (NK1 receptor) antagonists. Can. J. Physiol. Pharmacol. 80: 489-494. doi:10.1139/y02-048.
24. Sergeyev, V., Hokfelt, T., and Hurd, Y. 1999. Serotonin and substance P co-exist in dorsal raphe neurons of the human brain. Neuroreport, 10: 3967-3970. doi:10.1097/00001756-199912160-00044.
25. Soler, F., Plenge-Tellechea, F., Fortea, I., and Fernandez-Belda, F. 2000. Clomipramine and related structures as inhibitors of the skeletal sarcoplasmic reticulum Ca2+ pump. J. Bioenerg. Biomembr. 32: 133-142. doi:10.1023/A:1005519312463.
26. Southwell, B.R., and Furness, J.B. 2001. Immunohistochemical demonstration of the NK(1) tachykinin receptor on muscle and epithelia in guinea pig intestine. Gastroenterology, 120: 1140-1151. doi:10.1053/gast.2001. 23251.
27. Srinivasan, K., Ashok, M.V., Vaz, M., and Yeragani, V.K. 2004. Effect of imipramine on linear and nonlinear measures of heart rate variability Children. Pediatr. Cardiol. 25: 20-25. doi:10.1007/s00246-003-0468-5.
28. Taragano, F.E., Bagnatti, P., and Allegri, R.F. 2005. A double-blind, randomized clinical trial to assess the augmentation with nimodipine of antidepressant therapy in the treatment of "vascular depression". Int. Psychogeriatr. 17: 487-498. doi:10.1017/S1041610205001493.
29. Teixeira, R.M., Santos, A.R., Ribeiro, S.J., Calixto, J.B., Rae, G.A., and De Lima, T.C. 1996. Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice. Eur. J. Pharmacol. 311: 7-14. doi:10.1016/0014-2999(96)00390-1.
30. Traboulsie, A., Chemin, J., Kupfer, E., Nargeot, J., and Lory, P. 2006. T-type calcium channels are inhibited by fluoxetine and its metabolite norfluoxetine. Mol. Pharmacol. 69: 1963-1968. doi:10.1124/mol.105.020842.
31. Van Rossum, J.M. 1963. Cumulative dose-response curves.II. Technique for making of dose-response curves in isolated organs and the evaluation of drug parameters. Arch. Int. Pharmacod. T. 143: 299-330.
32. Watts, J.A., Yates, K.M., Badar, S.K., Marcengill, M.B., and Kline, J.A. 1998. Mechanisms ofCa2+antagonism in imipramine-induced toxicity of isolated adult rat cardiomyocytes. Toxicol. Appl. Pharmacol. 153: 95-101. doi:10.1006/taap.1998.8542.